IR Biosciences Holdings Inc.
IRBS · OTC
12/31/2010 | 12/31/2009 | 12/31/2008 | 12/31/2007 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -2,556,645.48% | -21,832,172.66% | -40,503,577.47% | -21,721,090.88% |
| EV / EBITDA | -1.02 | -1.35 | -0.73 | 0.04 |
| Quality | ||||
| ROIC | 101.95% | 446.60% | -195.79% | 1,018.54% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.08 | 0.45 | 0.82 | 0.45 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 85.05% | 39.91% | -93.03% | -19.98% |
| Safety | ||||
| Net Debt / EBITDA | -1.02 | -1.35 | -0.73 | 0.04 |
| Interest Coverage | -1.68 | -1.45 | -6.41 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |